The dose most commonly used in clinical trials is IVM 0.2–0.6 mg/kg PO given as a single dose or as a once-daily dose for up to 5 days.
Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19
Not sure how hospitals, doctors, and pharmacists are getting around this unequivocal approval by NIH, but they are as we all know. If you have to argue or plead with a health obstructionist, this may help your case. ABN
